The extrapulmonary effects of increasing doses of formoterol in patients with asthma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-04

AUTHORS

C. D. Burgess, M. Ayson, S. Rajasingham, J. Crane, G. Della Cioppa, M. D. Till

ABSTRACT

Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96 μg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9 h following each dose. Results: There was no difference between the maximum effects of formoterol 12 μg and placebo; the 24 μg dose significantly decreased plasma K (−0.2 mmol · l−1) and increased blood glucose (1.8 mmol · l−1) compared to placebo. The two highest doses affected most of the variables with the 96 μg dose being significantly different from placebo for all indices, heart rate (9 beats · min−1), systol BP (4 mmHg), diastolic BP (−3 mmHg), QS2I (−11 ms), QTc (17 ms), plasma K (−0.5 mmol · l−1) and blood glucose (2.6 mmol · l−1). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance. More... »

PAGES

141-147

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002280050435

DOI

http://dx.doi.org/10.1007/s002280050435

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050389605

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9626918


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Formoterol Fumarate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemodynamics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Potassium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burgess", 
        "givenName": "C. D.", 
        "id": "sg:person.01334442376.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334442376.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ayson", 
        "givenName": "M.", 
        "id": "sg:person.0612257664.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612257664.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rajasingham", 
        "givenName": "S.", 
        "id": "sg:person.0660373064.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660373064.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ", 
          "id": "http://www.grid.ac/institutes/grid.29980.3a", 
          "name": [
            "Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crane", 
        "givenName": "J.", 
        "id": "sg:person.0625622631.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625622631.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ciba-Geigy Ltd, Basel, Switzerland, CH", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Ciba-Geigy Ltd, Basel, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Della Cioppa", 
        "givenName": "G.", 
        "id": "sg:person.0652147271.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652147271.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ciba-Geigy Ltd, Basel, Switzerland, CH", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Ciba-Geigy Ltd, Basel, Switzerland, CH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Till", 
        "givenName": "M. D.", 
        "id": "sg:person.01163017140.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163017140.29"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00615959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002416913", 
          "https://doi.org/10.1007/bf00615959"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-04", 
    "datePublishedReg": "1998-04-01", 
    "description": "Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96\u2009\u03bcg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9\u2009h following each dose. Results: There was no difference between the maximum effects of formoterol 12\u2009\u03bcg and placebo; the 24\u2009\u03bcg dose significantly decreased plasma K (\u22120.2\u2009mmol\u200a\u00b7\u200al\u22121) and increased blood glucose (1.8\u2009mmol\u200a\u00b7\u200al\u22121) compared to placebo. The two highest doses affected most of the variables with the 96\u2009\u03bcg dose being significantly different from placebo for all indices, heart rate (9\u2009beats\u200a\u00b7\u200amin\u22121), systol BP (4\u2009mmHg), diastolic BP (\u22123\u2009mmHg), QS2I (\u221211\u2009ms), QTc (17\u2009ms), plasma K (\u22120.5\u2009mmol\u200a\u00b7\u200al\u22121) and blood glucose (2.6\u2009mmol\u200a\u00b7\u200al\u22121). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002280050435", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "54"
      }
    ], 
    "keywords": [
      "doses of formoterol", 
      "blood glucose", 
      "heart rate", 
      "plasma K", 
      "double-blind design", 
      "dry powder inhaler", 
      "electrocardiographic QTc interval", 
      "dose-dependent effect", 
      "formoterol 12", 
      "moderate asthma", 
      "extrapulmonary effects", 
      "blood pressure", 
      "electromechanical systole", 
      "diastolic BP", 
      "QTc interval", 
      "plasma potassium", 
      "clinical significance", 
      "powder inhaler", 
      "high dose", 
      "placebo", 
      "formoterol", 
      "high doses", 
      "separate days", 
      "doses", 
      "metabolic response", 
      "dose", 
      "FEV1", 
      "asthma", 
      "patients", 
      "maximum effect", 
      "glucose", 
      "QS2I", 
      "QTc", 
      "inhaler", 
      "systole", 
      "effect", 
      "days", 
      "rate", 
      "response", 
      "interval", 
      "index", 
      "differences", 
      "significance", 
      "potassium", 
      "BP", 
      "pressure", 
      "variables", 
      "measurements", 
      "design"
    ], 
    "name": "The extrapulmonary effects of increasing doses of formoterol in patients with asthma", 
    "pagination": "141-147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050389605"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002280050435"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9626918"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002280050435", 
      "https://app.dimensions.ai/details/publication/pub.1050389605"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_288.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002280050435"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050435'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      21 PREDICATES      95 URIs      86 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002280050435 schema:about N0f63bbcfd1404c7ab7d249670943a004
2 N156453c1a9504cde827fdbbf6f66b556
3 N2058be0f9cf74636ad823d0e92695445
4 N23a5026fb69f41eca7ef0736e8bc221c
5 N34c896a38e1b43d286af758de9f755f8
6 N3a4cce0ed0ae4522b35745cf0172d31e
7 N4035e360234744bab1f259632f0fcd20
8 N4beeff2909cd4fcf99f766c67928c49c
9 N4d5c3e9bf782447282acf718f996c40c
10 N7bb2c5b34d6c46e1a1b9211917db9035
11 N9e2a2204201a49cda14505835eb0260e
12 N9ece4b7b38ed48f3bb87c80cf8677f12
13 Ncadd0feb408b445eade68d822b4d61a0
14 Ne11663571e5046019bccf556920052a9
15 Ne598652180894a14805fb2a2767af54a
16 Ne666511e34f94dc1abc22e5b90270a56
17 Necee14834ece4a2486c19f16381d0924
18 Nf11fe35143f7497683e4194f8647db33
19 Nfa73b7064af84be79beaece8a65c46a1
20 anzsrc-for:11
21 anzsrc-for:1102
22 schema:author N8fc186da953f4281b812e88988cef7ea
23 schema:citation sg:pub.10.1007/bf00615959
24 schema:datePublished 1998-04
25 schema:datePublishedReg 1998-04-01
26 schema:description Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96 μg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9 h following each dose. Results: There was no difference between the maximum effects of formoterol 12 μg and placebo; the 24 μg dose significantly decreased plasma K (−0.2 mmol · l−1) and increased blood glucose (1.8 mmol · l−1) compared to placebo. The two highest doses affected most of the variables with the 96 μg dose being significantly different from placebo for all indices, heart rate (9 beats · min−1), systol BP (4 mmHg), diastolic BP (−3 mmHg), QS2I (−11 ms), QTc (17 ms), plasma K (−0.5 mmol · l−1) and blood glucose (2.6 mmol · l−1). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf Necf0423fa641408ab57dff493767d956
30 Nf64402f7972e43d2ab29e5fa7f289ab4
31 sg:journal.1054337
32 schema:keywords BP
33 FEV1
34 QS2I
35 QTc
36 QTc interval
37 asthma
38 blood glucose
39 blood pressure
40 clinical significance
41 days
42 design
43 diastolic BP
44 differences
45 dose
46 dose-dependent effect
47 doses
48 doses of formoterol
49 double-blind design
50 dry powder inhaler
51 effect
52 electrocardiographic QTc interval
53 electromechanical systole
54 extrapulmonary effects
55 formoterol
56 formoterol 12
57 glucose
58 heart rate
59 high dose
60 high doses
61 index
62 inhaler
63 interval
64 maximum effect
65 measurements
66 metabolic response
67 moderate asthma
68 patients
69 placebo
70 plasma K
71 plasma potassium
72 potassium
73 powder inhaler
74 pressure
75 rate
76 response
77 separate days
78 significance
79 systole
80 variables
81 schema:name The extrapulmonary effects of increasing doses of formoterol in patients with asthma
82 schema:pagination 141-147
83 schema:productId N85695f529468428a8e354a3e6a67ff15
84 Nc7bcdfbc15c64e36959a9ade1a4bdd34
85 Nf3f1300037c54e259c1ea8f404d8b2ca
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050389605
87 https://doi.org/10.1007/s002280050435
88 schema:sdDatePublished 2022-10-01T06:30
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher Nc1996a9428fb41c3a542ff91bb2de53e
91 schema:url https://doi.org/10.1007/s002280050435
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N0f63bbcfd1404c7ab7d249670943a004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Administration, Inhalation
97 rdf:type schema:DefinedTerm
98 N151ce5f1ab8b47c293589779f736bc93 rdf:first sg:person.0625622631.63
99 rdf:rest N1a412e52289d41548fa7508632a7230b
100 N156453c1a9504cde827fdbbf6f66b556 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Formoterol Fumarate
102 rdf:type schema:DefinedTerm
103 N16120d835daf4677baff35d9558609de rdf:first sg:person.0612257664.28
104 rdf:rest N941af6f5365b4a349eecdaa11b02765d
105 N1a412e52289d41548fa7508632a7230b rdf:first sg:person.0652147271.70
106 rdf:rest N60f9c0c743ab4a7d935518fd01dff89c
107 N2058be0f9cf74636ad823d0e92695445 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Ethanolamines
109 rdf:type schema:DefinedTerm
110 N23a5026fb69f41eca7ef0736e8bc221c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Asthma
112 rdf:type schema:DefinedTerm
113 N34c896a38e1b43d286af758de9f755f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 N3a4cce0ed0ae4522b35745cf0172d31e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Middle Aged
118 rdf:type schema:DefinedTerm
119 N4035e360234744bab1f259632f0fcd20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Bronchodilator Agents
121 rdf:type schema:DefinedTerm
122 N4beeff2909cd4fcf99f766c67928c49c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Double-Blind Method
124 rdf:type schema:DefinedTerm
125 N4d5c3e9bf782447282acf718f996c40c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adrenergic beta-Agonists
127 rdf:type schema:DefinedTerm
128 N60f9c0c743ab4a7d935518fd01dff89c rdf:first sg:person.01163017140.29
129 rdf:rest rdf:nil
130 N7bb2c5b34d6c46e1a1b9211917db9035 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Dose-Response Relationship, Drug
132 rdf:type schema:DefinedTerm
133 N85695f529468428a8e354a3e6a67ff15 schema:name doi
134 schema:value 10.1007/s002280050435
135 rdf:type schema:PropertyValue
136 N8fc186da953f4281b812e88988cef7ea rdf:first sg:person.01334442376.07
137 rdf:rest N16120d835daf4677baff35d9558609de
138 N941af6f5365b4a349eecdaa11b02765d rdf:first sg:person.0660373064.00
139 rdf:rest N151ce5f1ab8b47c293589779f736bc93
140 N9e2a2204201a49cda14505835eb0260e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 N9ece4b7b38ed48f3bb87c80cf8677f12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Blood Glucose
145 rdf:type schema:DefinedTerm
146 Nc1996a9428fb41c3a542ff91bb2de53e schema:name Springer Nature - SN SciGraph project
147 rdf:type schema:Organization
148 Nc7bcdfbc15c64e36959a9ade1a4bdd34 schema:name pubmed_id
149 schema:value 9626918
150 rdf:type schema:PropertyValue
151 Ncadd0feb408b445eade68d822b4d61a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Drug Administration Schedule
153 rdf:type schema:DefinedTerm
154 Ne11663571e5046019bccf556920052a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hemodynamics
156 rdf:type schema:DefinedTerm
157 Ne598652180894a14805fb2a2767af54a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Cross-Over Studies
159 rdf:type schema:DefinedTerm
160 Ne666511e34f94dc1abc22e5b90270a56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Time Factors
162 rdf:type schema:DefinedTerm
163 Necee14834ece4a2486c19f16381d0924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Potassium
165 rdf:type schema:DefinedTerm
166 Necf0423fa641408ab57dff493767d956 schema:volumeNumber 54
167 rdf:type schema:PublicationVolume
168 Nf11fe35143f7497683e4194f8647db33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Adult
170 rdf:type schema:DefinedTerm
171 Nf3f1300037c54e259c1ea8f404d8b2ca schema:name dimensions_id
172 schema:value pub.1050389605
173 rdf:type schema:PropertyValue
174 Nf64402f7972e43d2ab29e5fa7f289ab4 schema:issueNumber 2
175 rdf:type schema:PublicationIssue
176 Nfa73b7064af84be79beaece8a65c46a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
183 schema:name Cardiorespiratory Medicine and Haematology
184 rdf:type schema:DefinedTerm
185 sg:journal.1054337 schema:issn 0031-6970
186 1432-1041
187 schema:name European Journal of Clinical Pharmacology
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01163017140.29 schema:affiliation grid-institutes:grid.419481.1
191 schema:familyName Till
192 schema:givenName M. D.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163017140.29
194 rdf:type schema:Person
195 sg:person.01334442376.07 schema:affiliation grid-institutes:grid.29980.3a
196 schema:familyName Burgess
197 schema:givenName C. D.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334442376.07
199 rdf:type schema:Person
200 sg:person.0612257664.28 schema:affiliation grid-institutes:grid.29980.3a
201 schema:familyName Ayson
202 schema:givenName M.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612257664.28
204 rdf:type schema:Person
205 sg:person.0625622631.63 schema:affiliation grid-institutes:grid.29980.3a
206 schema:familyName Crane
207 schema:givenName J.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625622631.63
209 rdf:type schema:Person
210 sg:person.0652147271.70 schema:affiliation grid-institutes:grid.419481.1
211 schema:familyName Della Cioppa
212 schema:givenName G.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652147271.70
214 rdf:type schema:Person
215 sg:person.0660373064.00 schema:affiliation grid-institutes:grid.29980.3a
216 schema:familyName Rajasingham
217 schema:givenName S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660373064.00
219 rdf:type schema:Person
220 sg:pub.10.1007/bf00615959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002416913
221 https://doi.org/10.1007/bf00615959
222 rdf:type schema:CreativeWork
223 grid-institutes:grid.29980.3a schema:alternateName Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ
224 schema:name Department of Medicine, Wellington School of Medicine, PO Box 7343 Wellington South, Wellington, New Zealand, Tel.: +64 4 385 5999, Fax: +64 4 389 5427, e-mail: hbark@wnmeds.ac.nz, NZ
225 rdf:type schema:Organization
226 grid-institutes:grid.419481.1 schema:alternateName Ciba-Geigy Ltd, Basel, Switzerland, CH
227 schema:name Ciba-Geigy Ltd, Basel, Switzerland, CH
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...